Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Part 13 of an ongoing series, Jens D. Lundgren, MD, DMSc, provides a brief update monoclonal antibody treatments for COVID-19, including the FDA Emergency Use Authorization for bamlanivimab and discusses the recently released information on COVID-19 vaccine efficacy. After the update, Professor Lundgren answers clinician questions on various aspects of COVID-19.
Presenter:
Jens D. Lundgren, MD, DMSc
Professor
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
